{
  "id": "mhgap#risk_safety_df8e8746",
  "content": "y Group SSRIs and benzodiazepines had significantly\nnon-specialist settings.\nmore discontinuations due to adverse effects than\ny Almost all evidence refers to HICs. Further research\npill placebo. Treatment-emergent suicidality was\nis needed in LMICs.\nsignificantly greater in paroxetine-treated children\nand adolescents compared with those receiving\nImplementation considerations\nplacebo, and significantly lower in sertraline-treated\ny Access to psychotherapy, particularly cognitive\nchildren and adolescents compared with those\nbehavioural interventions and caregiver\nreceiving placebo. The available evidence points\nskills training, in line with other mhGAP\nto the fact that there is a lack of reliable data on\nrecommendations, remains important for children\nsuicidality for many pharmacological treatments for\nwith anxiety disorders and their caregivers.\n43\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nRecommendation (new): 4.2 Antidepressant medicines are not recommended for the treatment of\nchildren 12 years of age and below with depressive episode/disorder.\nStrength of recommendation: Strong\nCertainty of evidence: Low\nJustification comprehensive assessment of determinants at a\ny Evidence was extracted from two meta-analyses: family level and in the environment to reduce risks\nHetrick et al., 2021 (26 RCTs) (76); and Zhou et al., of overmedicalization.\n2020 (71 RCTs) (77).\nResearch gaps",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "high",
    "topics": [
      "relationships",
      "risk_safety",
      "screening_cues",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety y Group SSRIs and benzodiazepines had significantly\nnon-specialist settings.\nmore discontinuations due to adverse effects than\ny Almost all evidence refers to HICs. Further research\npill placebo. Treatment-emergent suicidality was\nis needed in LMICs.\nsignificantly greater in paroxetine-treated children\nand adolescents compared with those receiving\nImplementation considerations\nplacebo, and significantly lower in sertraline-treated\ny Access to psychotherapy, particularly cognitive\nchildren and adolescents compared with those\nbehavioural interventions and caregiver\nreceiving placebo. The available evidence points\nskills training, in line with other mhGAP\nto the fact that there is a lack of reliable data on\nrecommendations, remains important for children\nsuicidality for many pharmacological treatments for\nwith anxiety disorders and their caregivers.\n43\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\nRecommendation (new): 4.2 Antidepressant medicines are not recommended for the treatment of\nchildren 12 years of age and below with depressive episode/disorder.\nStrength of recommendation: Strong\nCertainty of evidence: Low\nJustification comprehensive assessment of determinants at a\ny Evidence was extracted from two meta-analyses: family level and in the environment to reduce risks\nHetrick et al., 2021 (26 RCTs) (76); and Zhou et al., of overmedicalization.\n2020 (71 RCTs) (77).\nResearch gaps Y group ssris and benzodiazepines had significantly\nnon-specialist settings. more discontinuations due to adverse effects than\ny almost all evidence refers to hics."
}